Markets

RTX Corporation (NYSE: RTX), through its Pratt & Whitney division, has been awarded a $3.8 billion contract modification by the U.S. Department of Defense for F135 engines supporting the F-35 Lightning II program. The multi-year award covers Lots 18 and 19, spanning all three F-35 variants — the F-35A, F-35B, and F-35C — for both […]

Citigroup raised its 12-month price target for Northrop Grumman Corporation (NYSE: NOC) to $807 from $781, while maintaining a Buy rating, in a research note dated April 2, 2026. The revised target implies approximately 17% upside from the April 2, 2026 close of $690.50. The note reflects increased confidence in Northrop’s margin expansion trajectory as

Lyft, Inc. (NASDAQ: LYFT) delivered record operational and financial results in the fourth quarter of 2025, with total revenue reaching $1.6 billion — up 3% year-over-year — as the company navigated a competitive rideshare market. The quarter marked consecutive periods of GAAP profitability, a milestone that has shifted investor focus toward Lyft’s long-term margin potential.

Delta Air Lines (NYSE: DAL) reported its first quarter 2026 earnings results today. Operating revenue increased 13% year-over-year to $15.8 billion. GAAP net loss was $289 million, or $0.44 per share, compared to net income of $240 million, or $0.37 per share, last year. Adjusted EPS rose 44% to $0.64. For the second quarter of 2026,

Shares of Lennar Corporation (NYSE: LEN) were down 3% on Tuesday. The stock has dropped 19% in the past three months. The homebuilder continues to face challenges from a difficult housing market which in turn continue to impact its quarterly performance. The company has been following a consistent strategy to navigate these headwinds rather than

In a market where most restaurant chains are struggling to balance growth with profitability, CAVA Group is attempting something tricky, scale fast without breaking the business. At first glance, CAVA looks like a classic growth story. A fast-casual brand riding the “healthy eating” wave, expanding aggressively, and winning over urban consumers. But when you dig

Johnson & Johnson (NYSE: JNJ) ended fiscal 2025 on a high note, reporting higher revenues and strong earnings growth for the fourth quarter. The company’s market position remains solid, supported by its diversified healthcare portfolio and resilient balance sheet. A bellwether for the broader healthcare sector, it is well-positioned to navigate periods of segment-specific volatility.